Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tanzisertib (CC-930) (CC-930) is a potent inhibitor of JNK1/2/3 with IC50s of 61/7/6 nM, respectively, with potential antifibrotic activity.
説明 | Tanzisertib (CC-930) (CC-930) is a potent inhibitor of JNK1/2/3 with IC50s of 61/7/6 nM, respectively, with potential antifibrotic activity. |
ターゲット&IC50 | JNK3:6 nM, JNK1:61 nM, JNK2:7 nM |
In vitro | Tanzisertib (CC-930) inhibits the formation of phospho-cJun in human PBMC stimulated by phorbol-12-myristate-13-acetate and phytohemeagglutinin (IC50=1 μM)[1] and it blocks the JNK pathway that is activated by pro-fibrotic cytokines in systemic sclerosis[3]. Tanzisertib (CC-930) (1-2 μM) substantially reduces hepatocyte apoptosis and necrosis, abrogates apoptosis and necrosis in FC-loaded WT hepatocytes[2]. |
In vivo | Tanzisertib (CC-930), when administered orally at doses of 10 and 30 mg/kg, decreases TNFa production by 23% and 77% respectively in the acute rat LPS-induced TNFa production PK-PD model[1]. Additionally, at a dose of 150 mg/kg, Tanzisertib (CC-930) not only prevents the development of fibrosis across various models but also reverses pre-existing fibrosis[3]. |
別名 | CC-930 |
分子量 | 448.44 |
分子式 | C21H23F3N6O2 |
CAS No. | 899805-25-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 33 mg/mL (73.59 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Tanzisertib 899805-25-5 MAPK JNK CC 930 Inhibitor inhibit CC930 CC-930 inhibitor